Identification of a novel nonsense mutation in the UNC13D gene from a patient with hemophagocytic lymphohistiocytosis: a case report

Hemophagocytic lymphohistiocytosis (HLH) is a heterogeneous and potentially fatal disease that presents with symptoms of persistent fever, splenomegaly and cytopenia. The first case was reported in 1952 by Farquhar et al. [1]; uncontrolled proliferation of activated macrophages and T lymphocytes are hallmarks of this syndrome [2]. Two types of HLH were described: a primary and a secondary form [3]. Primary HLH, also termed familial hemophagocytic lymphohistiocytosis (FHL), is an autosomal recessive genetic disorder with five major causative genes, namely, HPLH1, PRF1, UNC13D, STX11 and STXBP2 (Table 1) [4]. The incidence of FHL was estimated to approximately 1:100000 and 1:50000, respectively, according to two independent studies [5, 6]; however, worldwide, the incidence of FHL is still unclear. The secondary HLH, or acquired HLH, is mostly caused by the strong immunological activation of the immune system (e.g., severe infection of virus) rather than genetic mutations, but it may also develop during malignancies. It is difficult to distinguish these two types of HLH from each other, which necessitates an approach to differential diagnoses.

Here, we performed high-throughput amplicon sequencing to detect mutations in whole exons of 6 HLH-related genes for an 8-month-old female patient, who was diagnosed with HLH based on HLH-2004 guidelines [7]. As a result, 9 heterozygous variations, namely, 7 SNPs, one nonsense mutation (c.2206C > T) and one splicing mutation (c.2709 + 1G > A), in the UNC13D gene were detected. The nonsense mutation was reported in HLH for the first time. The compound heterozygous mutations in the UNC13D gene were considered causative mutations for the patient based on previous studies and functional predictions. A two-generation pedigree analysis showed that they were inherited from the parents. The result suggests great potential of high-throughput amplicon sequencing in the diagnosis of HLH.

This study was approved by the ethics committee on the use of human subjects at Wuhan Children’s Hospital. Informed consent from the patient’s parents was obtained before collecting blood samples. The patient and her parents are all Han Chinese from Hubei province of China.

This 8-month-old female patient was admitted to Wuhan Children’s Hospital after 2 days of fever, with a temperature measured at 39.0 °C on regular examination. Blood analysis showed low platelets (PLT, 45 × 10⁹/L) and low hemoglobin (Hb, 7.7 g/100 mL). Low NK cell activity (4.45%) and plasma albumin (18.2 g/L) were also observed. Moderate splenomegaly was revealed by ultrasound examination. The bone marrow examination suggested hemophagocytosis (Fig. 1), and no features of malignancy were observed. Since six of the eight criteria of HLH-2004 were fulfilled [7], this patient was diagnosed with HLH. To confirm the subtype of HLH and to investigate causative mutations in this patient, high-throughput amplicon sequencing and two-generation pedigree analysis were performed.

Genomic DNA was purified from peripheral blood mononuclear cells (PBMCs) with a commercial kit purchased from TIANGEN Biotech (Beijing, China). Multiple PCR primers were designed for 6 genes using Ion AmpliSeq™ Designer (Table 1); the SH2D1A and XIAP genes were included for distinguishing X-linked lymphoproliferative syndrome (XLP), which has a strong resemblance to HLH [8]. All exons of these genes were covered by 198 amplicons, including 5 bp of padding region. High-throughput amplicon sequencing was performed using an ION S5XL genetic analyzer (Thermo Fisher Scientific, MA, USA). VariantCaller V1.0 was used to detect mutations from sequencing data.

As a result, 9 heterozygous variations were detected, namely, 5 synonymous mutations, one missense mutation, one noncoding region mutation, one nonsense mutation and one splicing mutation (Table 2). All mutations were considered to be benign according to the dbSNP database except for the nonsense mutation NM_199242.2:c.2206C > T and the splicing mutation NM_199242.2:c.2709 + 1G > A. The splicing mutation c.2709 + 1G > A has been reported in patients with HLH with compound heterozygous mutations in the UNC13D gene [9, 10], it was predicted to be broken wild-type donor site and most probably affecting splicing, according to the human splicing finder (HSF, version 3.1). However, the nonsense mutation c.2206C > T, which resulted in the introduction of a premature stop codon and produced truncated mRNA (p.Gln736X), was reported in HLH for the first time. The compound heterozygosity was considered to be causative in this case, based on functional alteration analysis and previous reports.

Both mutations were confirmed by Sanger sequencing, and a two-generation pedigree analysis was performed with the parents’ samples. The results showed these two mutations were inherited from the father and mother (Fig. 2), presenting a typical autosomal recessive mode of inheritance.

HLH is a heterogeneous disease with two major conditions and five subtypes; additionally, many other conditions can lead to the clinical picture of HLH, such as malignancies, rheumatoid disorders, and XLP [7]. Molecular diagnosis based on genetic tests provide a powerful tool for differential diagnoses of HLH, which is important for appropriate treatment. Bianca et al. reported an approach for the genetic screening of patients with HLH using targeted high-throughput sequencing of 12 related genes, which resulted in a diagnosis in 22 of 58 patients in the prospective cohort [11]. Further in-depth investigations of the phenotype-genotype relationship of HLH are required to develop better sequencing panels for diagnosis.

The UNC13D gene, which encodes a protein involved in the cytotoxic activity of T lymphocytes, was confirmed as a causative gene of familial HLH type 3. Pathogenic mutations in the UNC13D gene are very common in patients with HLH, as 17–19% of FHL patients from Turkey and Germany, 89% from Korea, and 30% from Japan were identified to have pathogenic mutations in the UNC13D gene [12‐14]. Compound heterozygosity in the UNC13D gene was also reported, especially in the splicing site [9, 10]. However, there has been no genetic investigation on a substantial number of HLH patients in China. In this case, we identified the causative mutations of this patient in 24 h, using our customized panel which was designed automatically with online tool and purchased from Thermo Fisher Scientific (MA, USA). Average base coverage depth of the 55 kb target region was 1070-fold, 96.44% of total base was sequenced more than 100-fold. The concordance rate of amplicon sequencing and sanger sequencing is 100% in this case. The cost of this approach is about 1/5 to 1/10 of whole exome sequencing. The application of high-throughput amplicon sequencing would be helpful to diagnose genetic disease with an efficient and cost-saving way.

In conclusion, compound heterozygosity consisting of a nonsense mutation (c.2206C > T) and a splicing mutation (c.2709 + 1G > A) in the UNC13D gene was identified in a patient with HLH using high-throughput amplicon sequencing. Both mutations were confirmed by Sanger sequencing and were inherited from the parents. Our results expand the spectrum of UNC13D mutations in Chinese patients with HLH and demonstrate the potential of high-throughput amplicon sequencing in the diagnosis of heterogeneous genetic disorders.